Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo

International Drug Control Policy: Background and U.S. Responses (CRS Report for Congress)

Premium   Purchase PDF for $24.95 (42 pages)
add to cart or subscribe for unlimited access
Release Date Revised March 19, 2015
Report Number RL34543
Report Type Report
Authors Liana Sun Wyler, Specialist in International Crime and Narcotics
Source Agency Congressional Research Service
Older Revisions
  • Premium   Revised March 16, 2015 (42 pages, $24.95) add
  • Premium   Revised Aug. 13, 2013 (47 pages, $24.95) add
  • Premium   Revised Jan. 14, 2013 (43 pages, $24.95) add
  • Premium   Revised Oct. 16, 2012 (42 pages, $24.95) add
  • Premium   Revised March 21, 2011 (52 pages, $24.95) add
  • Premium   Revised March 8, 2010 (46 pages, $24.95) add
  • Premium   Revised Aug. 24, 2009 (39 pages, $24.95) add
  • Premium   Revised Feb. 9, 2009 (37 pages, $24.95) add
  • Premium   Revised Aug. 28, 2008 (43 pages, $24.95) add
  • Premium   June 23, 2008 (42 pages, $24.95) add
Summary:

The global illegal drug trade represents a multi-dimensional challenge that has implications for U.S. national interests as well as the international community. Common illegal drugs trafficked internationally include cocaine, heroin, and methamphetamine. According to the U.S. intelligence community, international drug trafficking can undermine political and regional stability and bolster the role and capabilities of transnational criminal organizations in the drug trade. Key regions of concern include Latin America and Afghanistan, which are focal points in U.S. efforts to combat the production and transit of cocaine and heroin, respectively. Drug use and addiction have the potential to negatively affect the social fabric of communities, hinder economic development, and place an additional burden on national public health infrastructures. International Policy Framework and Debate International efforts to combat drug trafficking are based on a long-standing and robust set of multilateral commitments, to which the United States has committed. U.S. involvement in international drug control rests on the central premise that helping foreign governments to combat illicit drugs abroad will ultimately curb availability and use in the United States. To this end, the current Administration maintains the goal of reducing and eliminating the international flow of illegal drugs into the United States through international cooperation to disrupt the drug trade, interdiction efforts, and support for demand reduction. Despite multilateral commitments to curb the supply of illicit drugs, tensions appear at times between U.S. foreign drug policy and approaches advocated by independent observers and other members of the international community. In recent years, an increasing number of international advocates, including several former and sitting heads of state, have begun to call for a reevaluation of current prohibitionist-oriented international drug policies. Alternatives to the existing international drug control regime may include legalizing or decriminalizing certain drugs. Debates may also focus on shifting priorities and resources among various approaches to counternarcotics, including supply and demand reduction; the distribution of domestic and international drug control funding; and the relative balance of civilian, law enforcement, and military roles in anti-drug efforts. U.S. Counternarcotics Initiatives and Foreign Policy Options Several key U.S. strategies and initiatives outline the foundation of U.S. counternarcotics efforts internationally, including the U.S. National Drug Control Strategy and International Narcotics Control Strategy Report (INCSR), both of which are updated annually and congressionally mandated. Other major country and regional initiatives include the (1) Mérida Initiative and Strategy in Mexico; (2) Central American Citizen Security Partnership; (3) Caribbean Basin Security Initiative (CBSI); (4) U.S.-Colombia Strategic Development Initiative (CSDI); (5) U.S. Counternarcotics Strategy for Afghanistan; and (6) West Africa Cooperative Security Initiative (WACSI). Located within the Executive Office of the President, the Office of National Drug Control Policy (ONDCP) establishes U.S. counterdrug policies and goals, and coordinates the federal budget to combat drugs both domestically and internationally. Within the U.S. government, multiple civilian, military, law enforcement, and intelligence entities contribute to international drug control policy, including the U.S. Department of State, U.S. Agency for International Development, U.S. Department of Defense, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of the Treasury, and the Central Intelligence Agency. As an issue of international policy concern for more than a century, and as a subject of longstanding U.S. and multilateral policy commitment, U.S. counterdrug efforts have expanded to include a broad array of tools to attack the international drug trade, such as the following: • reducing drug production at the source, • combating drugs in transit, • dismantling international illicit drug networks, • reducing and preventing drug demand abroad, and • creating incentives for international cooperation on drug control. Congress has been involved in all aspects of U.S. international drug control policy, regularly appropriating funds for counterdrug initiatives, as well as conducting oversight activities on federal counterdrug programs and the scope of agency authorities and other counterdrug policies. For FY2016, the Administration has requested from Congress approximately $27.6 billion for all federal drug control programs, of which $1.6 billion is requested for international programs, including civilian and military U.S. foreign assistance. An additional $3.9 billion is requested for interdiction programs related to intercepting and disrupting foreign drug shipments en route to the United States.